Phuong Khanh (PK) Morrow, MD, serves as head of  the Takeda Oncology Therapeutic Area Unit, guiding the company's oncology R&D strategy and development portfolio. She previously was Chief Medical Officer of CRISPR Therapeutics, where she leads a team of physicians and scientists across development, regulatory, pharmacovigilance, medical affairs, clinical operations, biometrics, medical affairs, data management, and medical writing functions.  Previously, Dr. Morrow was Vice President of Development at Amgen, where she led teams to develop and successfully launch a broad range of oncology modalities. Prior to her tenure at Amgen, she was on the faculty of MD Anderson Cancer Center (MDACC), where she specialized in the treatment of young breast cancer patients and HER2-neu positive disease.

Dr. Morrow holds a medical degree from the University of Texas Medical School, where she was a member of the Alpha Omega Alpha Honor Medical Society. She completed her Internal Medicine Residency at Baylor College of Medicine. She then completed her hematology/oncology fellowship at MDACC, during which she received the Clifton D. Howe Award for Clinical Excellence in Medical Oncology, achieved the American Society of Oncology Young Investigator Award for her translational work in head and neck cancer, and served as the Lyndon Baines Johnson Chief Fellow.

Dr. Morrow joined the Reagan-Udall Foundation for the FDA Board of Directors in 2023.